Family

Loading Family data...

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other

Patent Owner(s)

Patent Owner	Address
BAYER PHARMA AKTIENGESELLSCHAFT	BERLIN

International Classification(s)

• C07D:HETEROCYCLIC COMPOUNDS
• G01N:INVESTIGATING OR ANALYSING MATERIALS BY DETERMININ....
• A61P:THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDI....

• [Classification Symbol]

• [Patents Count]

Inventor(s)

Inventor Name	Address	# of filed Patents	Total Citations
BÖMER, Ulf	Glienicke, DE	100	553
BERGER, Markus	Berlin, DE	102	412
GRAHAM, Keith	Berlin, DE	51	199
GREULICH, Heidi	Cambridge, US	22	26
KAPLAN, Bethany	Cambridge, US	6	0
KLAR, Ulrich	Berlin, DE	115	639
KORR, Daniel	Berlin, DE	18	175
MEYERSON, Matthew	Boston, US	50	830
MORTIER, Jeremie Xavier G	Berlin, DE	4	1
SÜLZLE, Detlev	Berlin, DE	43	89
SCHRÖDER, Jens	Weimar, DE	31	85
SCHULZE, Volker	Hohen Neuendorf, DE	47	189
SIEGEL, Franziska	Whippany, US	22	14
SIEGEL, Stephan	Berlin, DE	33	153

Cited Art Landscape

Load Citation

• No Cited Art to Display

Loading Cited Art Landscape...

Patent Citation Ranking

Forward Cite Landscape

Load Citation

• No Forward Cites to Display

Loading Forward Cite Landscape...

Maintenance Fees

Fee	Large entity fee	small entity fee	micro entity fee	due date
3.5 Year Payment	$1600.00	$800.00	$400.00	Jun 28, 2027
7.5 Year Payment	$3600.00	$1800.00	$900.00	Jun 28, 2031
11.5 Year Payment	$7400.00	$3700.00	$1850.00	Jun 28, 2035

Fee	Large entity fee	small entity fee	micro entity fee
Surcharge - 3.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge - 7.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge - 11.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge after expiration - Late payment is unavoidable	$700.00	$350.00	$175.00
Surcharge after expiration - Late payment is unintentional	$1,640.00	$820.00	$410.00

Full Text

US Patent Application No: 2023/0416,249

N-[2-({4-[3-(ANILINO)-4-OXO-4,5,6,7-TETRAHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-2-YL]PYRIDIN-3-YL)OXY)ETHYL]PROP-2-ENAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER

---

 

Legal Events